Skip to main content

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.

Publication ,  Journal Article
Armstrong, AJ
Published in: Oncology (Williston Park)
October 2014

Duke Scholars

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

October 2014

Volume

28

Issue

10

Start / End Page

881 / 883

Location

United States

Related Subject Headings

  • Taxoids
  • Survival Rate
  • Prostatic Neoplasms
  • Prognosis
  • Patient Selection
  • Male
  • Humans
  • Docetaxel
  • Clinical Trials as Topic
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J. (2014). In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park), 28(10), 881–883.
Armstrong, Andrew J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.Oncology (Williston Park) 28, no. 10 (October 2014): 881–83.
Armstrong, Andrew J. “In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.Oncology (Williston Park), vol. 28, no. 10, Oct. 2014, pp. 881–83.
Armstrong AJ. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Oncology (Williston Park). 2014 Oct;28(10):881–883.

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

October 2014

Volume

28

Issue

10

Start / End Page

881 / 883

Location

United States

Related Subject Headings

  • Taxoids
  • Survival Rate
  • Prostatic Neoplasms
  • Prognosis
  • Patient Selection
  • Male
  • Humans
  • Docetaxel
  • Clinical Trials as Topic
  • Antineoplastic Agents